Primary Biliary Cholangitis clinical trials at UCSF
2 in progress, 1 open to eligible people
Primary biliary cholangitis is a disease that damages the bile ducts in the liver. UCSF is recruiting for trials studying the effects of Seladelpar on patients with this condition. These studies focus on people with primary biliary cholangitis and compensated cirrhosis.
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
open to eligible people ages 18 years and up
To Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis.
San Francisco, California and other locations
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
Sorry, in progress, not accepting new patients
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
San Francisco, California and other locations
Last updated: